Latest Insider Transactions at Lumos Pharma, Inc. (LUMO)
This section provides a real-time view of insider transactions for Lumos Pharma, Inc. (LUMO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LUMOS PHARMA, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LUMOS PHARMA, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 12
2024
|
Joseph S Mc Cracken Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,721
-100.0%
|
-
|
|
Dec 12
2024
|
Lori D Lawley Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,284
-100.0%
|
-
|
|
Dec 12
2024
|
Bradley J Powers General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
27
-100.0%
|
-
|
|
Dec 12
2024
|
Bradley J Powers General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,307
-100.0%
|
-
|
|
Dec 12
2024
|
Aaron Schuchart Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,179
-100.0%
|
-
|
|
Dec 12
2024
|
Kevin M. Lalande Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
730,446
-100.0%
|
-
|
|
Dec 12
2024
|
Kevin M. Lalande Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,076
-100.0%
|
-
|
|
Dec 12
2024
|
Pisit Duke Pitukcheewanont Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,836
-100.0%
|
-
|
|
Dec 12
2024
|
Thomas A. Raffin Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,406
-100.0%
|
-
|
|
Dec 12
2024
|
An Van Es Johansson Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,100
-100.0%
|
-
|
|
Dec 12
2024
|
Chad Allen Johnson Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,076
-100.0%
|
-
|
|
Dec 12
2024
|
John C. Mc Kew Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,153
-100.0%
|
-
|
|
Dec 12
2024
|
Lota S. Zoth Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,187
-100.0%
|
-
|
|
Dec 12
2024
|
Richard J Hawkins Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
4,469
-100.0%
|
-
|
|
Dec 12
2024
|
Richard J Hawkins Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
753,093
-100.0%
|
-
|
|
Aug 06
2024
|
John C. Mc Kew Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,407
-21.21%
|
$3,407
$1.89 P/Share
|
|
Aug 01
2024
|
John C. Mc Kew Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,593
-9.02%
|
$1,593
$1.79 P/Share
|
|
Aug 01
2024
|
Lori D Lawley Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
229
-1.83%
|
$229
$1.79 P/Share
|
|
Jul 01
2024
|
Pisit Duke Pitukcheewanont Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
274
-1.6%
|
$548
$2.26 P/Share
|
|
Jun 01
2024
|
Pisit Duke Pitukcheewanont Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
320
-1.89%
|
$640
$2.25 P/Share
|
|
Apr 03
2024
|
John C. Mc Kew Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,214
-11.43%
|
$4,428
$2.77 P/Share
|
|
Apr 01
2024
|
Aaron Schuchart Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+13.02%
|
$2,000
$2.84 P/Share
|
|
Apr 01
2024
|
Richard J Hawkins Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,522
-0.2%
|
$3,044
$2.84 P/Share
|
|
Apr 01
2024
|
Richard J Hawkins Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+0.59%
|
$9,000
$2.84 P/Share
|
|
Apr 01
2024
|
John C. Mc Kew Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,036
-5.08%
|
$2,072
$2.84 P/Share
|
|
Apr 01
2024
|
John C. Mc Kew Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+8.93%
|
$4,000
$2.84 P/Share
|
|
Apr 01
2024
|
Pisit Duke Pitukcheewanont Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+26.17%
|
$12,000
$2.84 P/Share
|
|
Apr 01
2024
|
Lori D Lawley Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
274
-2.14%
|
$548
$2.84 P/Share
|
|
Apr 01
2024
|
Lori D Lawley Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+7.25%
|
$2,000
$2.84 P/Share
|
|
Apr 01
2024
|
Bradley J Powers General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
342
-5.14%
|
$684
$2.84 P/Share
|
|
Apr 01
2024
|
Bradley J Powers General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
900
+11.92%
|
$1,800
$2.84 P/Share
|
|
Feb 06
2024
|
John C. Mc Kew Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
438
-2.32%
|
$1,314
$3.03 P/Share
|
|
Feb 01
2024
|
John C. Mc Kew Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
366
-1.91%
|
$1,098
$3.01 P/Share
|
|
Feb 01
2024
|
Bradley J Powers General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
240
-4.01%
|
$720
$3.01 P/Share
|
|
Feb 01
2024
|
Aaron Schuchart Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
202
-3.43%
|
$606
$3.01 P/Share
|
|
Feb 01
2024
|
Lori D Lawley Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
215
-1.79%
|
$645
$3.01 P/Share
|
|
Feb 01
2024
|
Richard J Hawkins Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
690
-0.09%
|
$2,070
$3.01 P/Share
|
|
Aug 02
2023
|
John C. Mc Kew Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,407
-15.41%
|
$10,221
$3.21 P/Share
|
|
Aug 01
2023
|
Lori D Lawley Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
229
-1.95%
|
$687
$3.28 P/Share
|
|
Aug 01
2023
|
John C. Mc Kew Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,593
-6.72%
|
$4,779
$3.28 P/Share
|
|
Apr 04
2023
|
John C. Mc Kew Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,214
-8.71%
|
$6,642
$3.27 P/Share
|
|
Apr 01
2023
|
Richard J Hawkins Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,522
-0.2%
|
$4,566
$3.31 P/Share
|
|
Apr 01
2023
|
Lori D Lawley Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
274
-2.38%
|
$822
$3.31 P/Share
|
|
Apr 01
2023
|
John C. Mc Kew Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,036
-3.92%
|
$3,108
$3.31 P/Share
|
|
Apr 01
2023
|
Bradley J Powers General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
342
-5.4%
|
$1,026
$3.31 P/Share
|
|
Feb 02
2023
|
John C. Mc Kew Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
439
-1.63%
|
$1,317
$3.53 P/Share
|
|
Feb 01
2023
|
Richard J Hawkins Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
416
-0.06%
|
$1,248
$3.52 P/Share
|
|
Feb 01
2023
|
Richard J Hawkins Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+0.59%
|
$13,500
$3.52 P/Share
|
|
Feb 01
2023
|
David B Karpf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
36
-0.43%
|
$108
$3.52 P/Share
|
|
Feb 01
2023
|
David B Karpf Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+10.72%
|
$3,000
$3.52 P/Share
|